OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody –  drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024. OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an […]

This article is password protected.

To view the content, please enter your password in the field below